Bright Minds Biosciences (DRUG) announced the expansion of its Scientific Advisory Board to include five distinguished experts in epilepsy ...
The replay of the webcast will be accessible for 90 days. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders.
Piper Sandler analyst Yasmeen Rahimi initiated coverage with a Buy rating on Bright Minds Biosciences (DRUG – Research Report) today and set a price target of $93.00. The company’s shares ...
“We are fortunate to welcome these accomplished and highly respected researchers to the Bright Minds team at this exciting juncture. As we advance our clinical programs through the regulatory ...
The replay of the webcast will be accessible for 90 days. Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders.